Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.
Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.